Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression

Br J Haematol. 2020 Jul;190(2):e98-e101. doi: 10.1111/bjh.16738. Epub 2020 May 16.

Authors

Talha Badar¹, John Astle², Imran K Kakar³, Katie Zellner¹, Parameswaran N Hari¹, Mehdi Hamadani¹

Affiliations

¹ BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
² Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
³ Rawalpindi Medical College, Rawalpindi, Pakistan.

PMID: 32415780
DOI: 10.1111/bjh.16738

No abstract available

Keywords: BTK inhibitor; ITK; ibrutinib; relapsed refractory Hodgkin lymphoma.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Adult
Agammaglobulinaemia Tyrosine Kinase / metabolism*
Aged
Hematopoietic Stem Cell Transplantation / methods*
Hodgkin Disease / drug therapy*
Hodgkin Disease / genetics
Hodgkin Disease / therapy*
Humans
Middle Aged
Neoplasm Recurrence, Local
Piperidines
Transplantation Conditioning / methods*
Transplantation, Homologous / methods*

Substances

Piperidines
ibrutinib
Agammaglobulinaemia Tyrosine Kinase
BTK protein, human
Adenine